Summit Therapeutics SMMT Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's retained earnings?
- Summit Therapeutics (SMMT) reported retained earnings of -$2.48B in Q1 2026.
- How has Summit Therapeutics's retained earnings changed year-over-year?
- Summit Therapeutics's retained earnings decreased by 94.4% year-over-year, from -$1.28B to -$2.48B.
- What is the long-term trend for Summit Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Summit Therapeutics's retained earnings has grown at a 61.2% compound annual growth rate (CAGR), from -$210.95M to -$2.29B.
- What does retained earnings mean?
- The total historical net profit or loss that has been kept in the business rather than distributed as dividends.
- How do you interpret retained earnings?
- A positive, growing balance indicates sustained profitability, while a negative balance is common for early-stage biotech firms heavily investing in clinical trials.
- How does retained earnings compare across companies?
- Early-stage biotech companies typically show negative retained earnings due to high R&D spending compared to mature commercial-stage firms.